74 related articles for article (PubMed ID: 7882329)
1. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice.
Arakawa H; Iguchi T; Morita M; Yoshinari T; Kojiri K; Suda H; Okura A; Nishimura S
Cancer Res; 1995 Mar; 55(6):1316-20. PubMed ID: 7882329
[TBL] [Abstract][Full Text] [Related]
2. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
[TBL] [Abstract][Full Text] [Related]
3. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T
Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505
[TBL] [Abstract][Full Text] [Related]
4. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.
Takenaga N; Ishii M; Nakajima S; Hasegawa T; Iwasa R; Ishizaki H; Kamei T
Drug Metab Dispos; 1999 Feb; 27(2):205-12. PubMed ID: 9929504
[TBL] [Abstract][Full Text] [Related]
5. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
[TBL] [Abstract][Full Text] [Related]
6. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
7. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
[TBL] [Abstract][Full Text] [Related]
8. In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice.
Arakawa H; Morita M; Kodera T; Okura A; Ohkubo M; Morishima H; Nishimura S
Jpn J Cancer Res; 1999 Oct; 90(10):1163-70. PubMed ID: 10595746
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.
Ohkubo M; Kojiri K; Kondo H; Tanaka S; Kawamoto H; Nishimura T; Nishimura I; Yoshinari T; Arakawa H; Suda H; Morishima H; Nishimura S
Bioorg Med Chem Lett; 1999 May; 9(9):1219-24. PubMed ID: 10340602
[TBL] [Abstract][Full Text] [Related]
10. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
Balasubramanian BN; St Laurent DR; Saulnier MG; Long BH; Bachand C; Beaulieu F; Clarke W; Deshpande M; Eummer J; Fairchild CR; Frennesson DB; Kramer R; Lee FY; Mahler M; Martel A; Naidu BN; Rose WC; Russell J; Ruediger E; Solomon C; Stoffan KM; Wong H; Wright JJ; Zimmermann K; Vyas DM
J Med Chem; 2004 Mar; 47(7):1609-12. PubMed ID: 15027851
[TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
13. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.
Cavazos CM; Keir ST; Yoshinari T; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2001 Sep; 48(3):250-4. PubMed ID: 11592348
[TBL] [Abstract][Full Text] [Related]
15. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
Bailly C; Dassonneville L; Colson P; Houssier C; Fukasawa K; Nishimura S; Yoshinari T
Cancer Res; 1999 Jun; 59(12):2853-60. PubMed ID: 10383146
[TBL] [Abstract][Full Text] [Related]
16. Novel antitumor L-arabinose derivative of indolocarbazole with high affinity to DNA.
Kaluzhny DN; Tatarskiy VV; Dezhenkova LG; Plikhtyak IL; Miniker TD; Shchyolkina AK; Strel'tsov SA; Chilov GG; Novikov FN; Kubasova IY; Smirnova ZS; Mel'nik SY; Livshits MA; Borisova OF; Shtil AA
ChemMedChem; 2009 Oct; 4(10):1641-8. PubMed ID: 19672918
[TBL] [Abstract][Full Text] [Related]
17. ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice.
Arakawa H; Iguchi T; Yoshinari T; Kojiri K; Suda H; Okura A
Jpn J Cancer Res; 1993 May; 84(5):574-81. PubMed ID: 8320174
[TBL] [Abstract][Full Text] [Related]
18. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
19. [NB 506].
Lansiaux A; Bailly C
Bull Cancer; 1999 Mar; 86(3):255-8. PubMed ID: 10210758
[No Abstract] [Full Text] [Related]
20. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
